Tirzepatide
Tirzepatide
A dual GIP/GLP-1 receptor agonist studied for weight management and type 2 diabetes
Tirzepatide is a synthetic 39-amino acid peptide and the first dual agonist of the GIP and GLP-1 receptors. As of October 2026, it's an FDA-approved prescription medicine from Eli Lilly, sold as Mounjaro for type 2 diabetes and as Zepbound for weight management and obstructive sleep apnea in adults with obesity (a multi-dose KwikPen was added in February 2026). Research-use vials aren't the approved product, and FDA has warned companies selling tirzepatide labeled "for research purposes".
Read the research profile for mechanisms, citations, and safety context before comparing vendors. View the Tirzepatide research profile.
Key Benefits
Mechanism of Action
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Per the Zepbound label, this raises insulin release when blood sugar is high, lowers glucagon, improves insulin sensitivity and slows gastric emptying. The label says it also lowers calorie intake, likely by reducing appetite.
Dosing Guidelines
Typical Dose
2.5-15 mg weekly per the Zepbound label
Frequency
1x weekly
Duration
Long-term (SURMOUNT trials ran 72 weeks)
Note: The Zepbound label gives tirzepatide by subcutaneous injection once a week: 2.5 mg for 4 weeks (a starting dose only), then 5 mg, rising in 2.5 mg steps at least 4 weeks apart to a 5, 10 or 15 mg maintenance dose (15 mg max). The slow step-up is meant to reduce stomach side effects. Some forum users describe "microdosing" well below 2.5 mg; no trial has tested doses under 2.5 mg.
Research & Studies
Our profile of tirzepatide's mechanism, trial results, reported doses and side effects, for research purposes.
Read Full ResearchThe trial in adults with obesity or overweight that reported 20.9% mean weight loss at 72 weeks on tirzepatide 15 mg, vs 3.1% on placebo.
Read Full ResearchHow the two approved incretin drugs differ in mechanism, trial results and reported side effects.
Read Full ResearchPotential Side Effects
Reported side effects may include:
- - Nausea, the most common (25-29% vs 8% on placebo in label trials), mostly while the dose is raised
- - Diarrhea, constipation or vomiting (common in trials)
- - Decreased appetite
- - Abdominal pain, indigestion, belching and heartburn (trials)
- - Injection site reactions, fatigue and hair loss (about 5-8% each in trials)
- - Gallbladder disease and pancreatitis (label warnings)
- - Thyroid C-cell tumors in rats; boxed warning, human risk unknown
- - Diabetic retinopathy worsening in type 2 diabetes (label warning, 08/2026)
This information is for research purposes only. Always consult with a healthcare professional.
Popular Stacking Options
Tirzepatide + BPC-157
Some users add it hoping to ease GLP-1 nausea and gut discomfort, based on rodent gut studies. No study has tested the combination.
Shop this stackTirzepatide + Tesamorelin
Some users add it hoping to limit muscle loss and target visceral fat. It's approved only for abdominal fat in HIV-associated lipodystrophy, and no study has tested it with tirzepatide.
Shop this stackTirzepatide + Ipamorelin
Some users pair it hoping growth hormone release helps preserve lean mass. Human data are limited, and no study has tested the combination.
Shop this stackFrequently Asked Questions
Is Tirzepatide better than Semaglutide?
In head-to-head trials it produced more weight loss and larger blood sugar drops. In SURMOUNT-5 (751 adults with obesity, open-label, funded by Lilly), mean weight loss at 72 weeks was 20.2% on tirzepatide vs 13.7% on semaglutide 1.7-2.4 mg. The gap is usually credited to its added GIP action, which the trials didn't test. Individual response varies.
How do I manage the nausea from Tirzepatide?
Nausea is most common when starting or raising the dose, and the label's slow step-up is meant to reduce it. Users commonly describe smaller, bland meals, avoiding high-fat foods and staying hydrated; that's community practice, not a tested approach. Severe or persistent vomiting or stomach pain is a reason to see a healthcare professional.
Will I lose muscle while taking Tirzepatide?
Any large weight loss includes some lean mass, though the Zepbound label says tirzepatide causes more fat loss than lean-mass loss. Resistance training and adequate protein are the usual advice, but tirzepatide trials didn't test them. Some users add ipamorelin or tesamorelin hoping to preserve muscle; no study has tested those combinations.
How long does it take to see results?
Users commonly report less appetite within the first week or two. In SURMOUNT-1, weight loss built gradually during the step-up (up to 20 weeks) and continued after it, reaching 15.0-20.9% at 72 weeks on 5-15 mg alongside diet and activity counseling.
Do I have to take Tirzepatide forever?
Tirzepatide manages obesity and diabetes; it doesn't cure them. In a withdrawal trial in the Zepbound label, people switched to placebo after 36 weeks regained 14.0% of their weight over 52 weeks, while those who stayed on it lost another 5.5%. Any plan to stop is best made with a healthcare professional.
More from this category
Compare nearby options in the same category before choosing a research product.
AOD-9604
Growth hormone fragment studied for fat metabolism
Cagrilintide
A long-acting amylin analogue studied for appetite reduction and weight loss
MOTS-c
A mitochondrial-encoded peptide studied in mice for insulin sensitivity and exercise capacity.
Retatrutide
An investigational triple agonist (GIP, GLP-1 and glucagon receptors) studied for weight loss and metabolic health
You might also like
These peptides share research keywords or protocol overlap with Tirzepatide.
Semaglutide
A GLP-1 receptor agonist studied for weight management and type 2 diabetes
Ready to Purchase Tirzepatide?
Get pharmaceutical-grade Tirzepatide from Simple Peptide with 99%+ purity, third-party lab testing, and same-day dispatch.
Buy Tirzepatide Now